URINARY TRIAOSYLCERAMIDE (GB3) AS A MARKER OF CARDIAC DISEASE
摘要
<p>The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.</p>
申请公布号
WO2011063048(A3)
申请公布日期
2011.09.15
申请号
WO2010US57112
申请日期
2010.11.17
申请人
BAYLOR RESEARCH INSTITUTE;SCHIFFMANN, RAPHAEL;MOCHEL, FANNY;SWEETMAN, LAWRENCE;FORNI, SABRINA